From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care
Translational Behavioral Medicine · 07.01.2026 · 16 (1)
DOI: 10.1093/tbm/ibag027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Behavioral Medicine, online erschienen am 19.05.2026. Verfasst von Joshua Mitchell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Hou…. Hauptthemen laut MEDLINE: Hallucinogens, Translational Research, Biomedical, Research Personnel, Mental Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ethical Legal Implications of Psychedelics in Society (ELIPSIS), Ortus Foundation, Hollie Stenson Foundation.
Abstract (Originalsprache)
Background
Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move from tightly controlled clinical trials to routine clinical care.
Purpose
This study examines how psychedelic clinical investigators anticipate this transition and what challenges they expect.
Methods
We conducted semi-structured interviews with 21 clinical investigators based at major academic psychedelic research centers across the United States. We transcribed and analyzed these conversations using inductive and deductive coding to identify major themes.
Results
Investigators generally viewed psychedelic medicine as distinct from existing treatments, particularly in terms of drug effects, treatment models, and broader goals. They highlighted three major translational challenges: (i) uncertainty surrounding the role of psychotherapy, (ii) the cost of treatment and its scalability, and (iii) the effects of both hype and stigma on clinical uptake.
Conclusion
Despite these challenges, most investigators anticipated that psychedelic medicine could eventually fit into routine clinical care and may even improve it.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ethical Legal Implications of Pyshcedelics in Society (ELIPSIS) Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA.
- The Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
- The Menninger Clinic, Houston, TX, USA.
ORCID-Profile: Amy L McGuire
Förderung
- Ethical Legal Implications of Psychedelics in Society (ELIPSIS)
- Ortus Foundation
- Hollie Stenson Foundation
- Baylor College of Medicine
Zitieren
APA
Mitchell, J., Neitzke-Spruill, L., Mathai, D. S., Robinson, J. O., Kavan, Z., Averil, L. A., & McGuire, A. L. (2026). From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care. Translational Behavioral Medicine, 16(1). https://doi.org/10.1093/tbm/ibag027
Vancouver
Mitchell J, Neitzke-Spruill L, Mathai DS, Robinson JO, Kavan Z, Averil LA, et al. From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care. Translational Behavioral Medicine. 2026;16(1). doi:10.1093/tbm/ibag027
BibTeX
@article{Mitchell2026,
author = {Mitchell, Joshua and Neitzke-Spruill, Logan and Mathai, David S and Robinson, Jill O and Kavan, Zuzana and Averil, Lynnette A and McGuire, Amy L},
title = {From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care},
journal = {Translational Behavioral Medicine},
year = {2026},
volume = {16},
number = {1},
doi = {10.1093/tbm/ibag027}
}
EUVIMED